Michael Okunewitch
Stock Analyst at Maxim Group
(0.25)
# 4,059
Out of 4,829 analysts
23
Total ratings
13.64%
Success rate
-24.65%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.08 | +193.96% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.25 | +460.00% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $2.50 | +460.00% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.47 | +533.85% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $0.90 | +232.45% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.69 | +479.04% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.84 | +1,326.87% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.45 | +313.79% | 2 | Aug 27, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.09 | +1,001.62% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $1.25 | +1,827.71% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.97 | +517.92% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.19 | +464.26% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $5.29 | +38,179.77% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.70 | +33.69% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.84 | +226.09% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $160 | $5.43 | +2,846.59% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.43 | +1,648.25% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.74 | +13,411.69% | 1 | Nov 30, 2021 |
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.08
Upside: +193.96%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.25
Upside: +460.00%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $2.50
Upside: +460.00%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.47
Upside: +533.85%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $0.90
Upside: +232.45%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.69
Upside: +479.04%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.84
Upside: +1,326.87%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.45
Upside: +313.79%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.09
Upside: +1,001.62%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.25
Upside: +1,827.71%
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $0.97
Upside: +517.92%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.19
Upside: +464.26%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $5.29
Upside: +38,179.77%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.70
Upside: +33.69%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.84
Upside: +226.09%
Mar 24, 2022
Initiates: Buy
Price Target: $160
Current: $5.43
Upside: +2,846.59%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.43
Upside: +1,648.25%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.74
Upside: +13,411.69%